ELGART Jorge Federico
congresos y reuniones científicas
Sodium-glucose co-transporter 2 inhibitor in type 2 diabetes- prescription patterns and treatment outcomes in Argentina.
Congreso; ISPOR 7th Latin America Conference; 2019
Institución organizadora:
International Society for Pharmacoeconomics and outcomes research
OBJECTIVE: To assess prescription patterns for treatment of people with type 2 diabetes (T2D) with sodium-glucose co-transporter 2 inhibitors (SGLT2i) and their outcomes in Argentina.METHODS: Observational study performed using data from the QUALIDIAB database. We identified patients with T2D who were prescribed SGLT2i during 2017-2018 periods alone or associated with other antidiabetic drugs recording their clinical and metabolic indicators. Outcome measures analyzed included attainment of treatment goals defined as HbA1c ≤7%, blood pressure ≤130/80 mmHg, and LDL cholesterol ≤100 mg/dl. Descriptive statistics are presented as percentages and mean ± standard deviation (SD). Comparisons for continuous variables were analyzed by parametric or non-parametric test according to the data distribution profile. Chi-square test was used for proportions.RESULTS: Out of 2724 records of patients with T2D reviewed, 124 were prescribed a SGLT2i (4.5%), age 59.9±9.9 years, 46.8% women, duration of T2D 11.1±7.8 years, HbA1c 7.7±1.4%, LDL cholesterol 101.9±38.8mg/dl, body mass index 33.2±6.1, with microvascular (41.5%) and macrovascular (35.2%) complications and 95.2% with health coverage (84.7% social security and 10.5% private). 31.5% used SGLT2i combined with insulin (with or without oral glucose lowering drugs [OGLD]), while in patients treated without insulin SLGT2i was associated with metformin (32.9%) or 60% with other OGLD (with or without Metformin). The latter combined SGLT2i with metformin and iDPP-4 (45.1%). Regarding attainment of treatment goals: overall 36.7% have an HbA1c on target, 58.8% blood pressure ≤130/80mmHg and 54% LDL-c ≤100mg/dl. Patients treated with SLGT2i and metformin 66.7% attain a blood pressure ≤130/80mmHg and 57.1% HbA1c ≤7%, while among patients treated with SGLT2i, metformin and iDPP-4 59.1% have a blood pressure ≤130/80mmHg and 40.9% HbA1c ≤7%.CONCLUSIONS: These results facilitate our understanding on current prescription profile and outcomes of SGLT2i in people with T2D in Argentina.